Literature DB >> 32442118

Effects of Kinesio Taping on pain, paresthesia, functional status, and overall health status in patients with symptomatic thoracic outlet syndrome: A single-blind, randomized, placebo-controlled study.

Emine Aygül Ortaç1, Tunay Sarpel1, İlke Coşkun Benlidayı1.   

Abstract

OBJECTIVE: This study aimed to assess the effects of kinesio taping (KT) on pain, paresthesia, functional status, and overall health status in patients with symptomatic thoracic outlet syndrome (sTOS).
METHODS: A single-blind placebo-controlled design was employed in this study. The study duration was defined as 12 months. Analyses were performed on 60 patients with sTOS randomly assigned to KT (4 men and 26 women; mean age=33.5 years, range=20-46 years) and control groups (5 men and 25 women; mean age=26 years, range=20-43 years). KT was applied to the KT group three times. The control group received placebo taping. Pain and paresthesia were evaluated using the visual analogue scale (VAS) pain (10 cm) and VAS paresthesia (10 cm). The upper limb function was assessed using the disabilities of the arm, shoulder, and hand (DASH) questionnaire. The overall health status was evaluated based on the Nottingham Health Profile (NHP). Each assessment was carried out at baseline (t0), posttreatment (t1), and 8 weeks after baseline (t2).
RESULTS: In the KT group, except the social isolation domain of the NHP, all outcome measures showed improvement from t0 to t1. At the second follow-up visit (t2), improvements remained visible compared with baseline. However, none of the variables improved from t1 to t2. Otherwise, all measures deteriorated slightly, and the deteriorations in VAS for pain, NHP pain, NHP sleep, and NHP physical abilities were statistically significant (p=0.041, p=0.048, p=0.013, and p=0.016, respectively). In the control group, only VAS for paresthesia and NHP emotional reaction showed improvement over time (p=0.002 and p=0.044, respectively). When changes in outcome measures between the two groups were compared, except NHP emotional reaction and NHP social isolation, median changes (from t0 to t1) were higher in the KT group than in the control group (p<0.05 for all variables). Regarding VAS pain, VAS paresthesia, DASH, and three NHP domains (energy level, pain, and physical abilities), changes from t0 to t2 were also higher in the KT group (p<0.05 for all variables).
CONCLUSION: KT can provide benefits in terms of relieving pain and paresthesia, as well as improving the upper limb function and quality of life in patients with sTOS. LEVEL OF EVIDENCE: Level II, Therapeutic study.

Entities:  

Mesh:

Year:  2020        PMID: 32442118      PMCID: PMC7444878          DOI: 10.5152/j.aott.2020.19042

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  33 in total

Review 1.  The development of a subjective health indicator.

Authors:  S M Hunt; J McEwen
Journal:  Sociol Health Illn       Date:  1980-11

Review 2.  Etiology of neurogenic thoracic outlet syndrome.

Authors:  Charles O Brantigan; David B Roos
Journal:  Hand Clin       Date:  2004-02       Impact factor: 1.907

3.  The effect of Kinesiotape application on functional performance in surgeons who have musculo-skeletal pain after performing surgery.

Authors:  Nihan Karatas; Seda Bicici; Gul Baltaci; Hakan Caner
Journal:  Turk Neurosurg       Date:  2012       Impact factor: 1.003

Review 4.  Thoracic outlet syndrome part 2: conservative management of thoracic outlet.

Authors:  L A Watson; T Pizzari; S Balster
Journal:  Man Ther       Date:  2010-04-09

5.  Could forearm Kinesio Taping improve strength, force sense, and pain in baseball pitchers with medial epicondylitis?

Authors:  Hsiao-Yun Chang; Chun-Hou Wang; Kun-Yu Chou; Shih-Chung Cheng
Journal:  Clin J Sport Med       Date:  2012-07       Impact factor: 3.638

6.  The development and psychometric assessment of the Turkish version of the Nottingham Health Profile.

Authors:  A A Kücükdeveci; S P McKenna; S Kutlay; Y Gürsel; D Whalley; T Arasil
Journal:  Int J Rehabil Res       Date:  2000-03       Impact factor: 1.479

7.  Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG)

Authors:  P L Hudak; P C Amadio; C Bombardier
Journal:  Am J Ind Med       Date:  1996-06       Impact factor: 2.214

8.  Comparison of efficacy of kinesiological taping and subacromial injection therapy in subacromial impingement syndrome.

Authors:  Volkan Subaşı; Tuncay Çakır; Zuhal Arıca; Rahime Nur Sarıer; Meral Bilgilisoy Filiz; Şebnem Koldaş Doğan; Naciye Füsun Toraman
Journal:  Clin Rheumatol       Date:  2014-11-18       Impact factor: 2.980

9.  The effectiveness of the low-power laser and kinesiotaping in the treatment of carpal tunnel syndrome, a pilot study.

Authors:  A Güner; L Altan; M Kasapoğlu Aksoy
Journal:  Rheumatol Int       Date:  2018-03-28       Impact factor: 2.631

Review 10.  Diagnosing thoracic outlet syndrome.

Authors:  Charles O Brantigan; David B Roos
Journal:  Hand Clin       Date:  2004-02       Impact factor: 1.907

View more
  2 in total

1.  Derkash's Classification and Vas Visual Analog Scale to Access the Long-Term Outcome of Neurothoracic Outlet Syndrome: A Meta-Analysis and Systematic Review.

Authors:  Wei Lingyun; Sha Ke; Zhao Jinmin; Qiao Yu; Qin Jun
Journal:  Front Neurol       Date:  2022-07-06       Impact factor: 4.086

Review 2.  Thoracic Outlet Syndrome Part I: Systematic Review of the Literature and Consensus on Anatomy, Diagnosis, and Classification of Thoracic Outlet Syndrome by the European Association of Neurosurgical Societies' Section of Peripheral Nerve Surgery.

Authors:  Nora Franziska Dengler; Stefano Ferraresi; Shimon Rochkind; Natalia Denisova; Debora Garozzo; Christian Heinen; Ridvan Alimehmeti; Crescenzo Capone; Damiano Giuseppe Barone; Anna Zdunczyk; Maria Teresa Pedro; Gregor Antoniadis; Radek Kaiser; Annie Dubuisson; Thomas Kretschmer; Lukas Rasulic
Journal:  Neurosurgery       Date:  2022-03-25       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.